Vaxess co-founders (L-R): Livio Valenti, Michael Schrader, and Kathryn Kosuda (Credit: Vaxess)

Ex­clu­sive: As­traZeneca and Vaxess de­vel­op­ing skin patch mR­NA vac­cines for pan­dem­ic flu

As­traZeneca is de­vel­op­ing a nov­el type of mR­NA vac­cine that can be ad­min­is­tered as a shelf-sta­ble skin patch in­stead of a shot, po­ten­tial­ly mak­ing dis­tri­b­u­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.